Ressom Habtom W HW

Show results for

Metabolomics (3)
Proteomics (2)

Organisms

Alphavirus (2)
Anemia (2)
Betaherpesvirinae (2)
Cowpox virus (2)
Coxsackievirus (2)
Cytomegalovirus (2)
Dengue virus (2)
EFO:0001352 (2)
Filoviridae (2)
Hepatitis B virus (2)
Human alphaherpesvirus 1 (2)
Human betaherpesvirus 5 (2)
Human immunodeficiency virus (2)
Human immunodeficiency virus 1 (2)
Human immunodeficiency virus 2 (2)
Influenza A virus (2)
Influenza C virus (2)
Japanese encephalitis virus group (2)
Lyssavirus rabies (2)
Monkeypox virus (2)
Nostoc sp. PCC 7120 = FACHB-418 (2)
Oropouche virus (2)
Orthopoxvirus (2)
Orthopoxvirus vaccinia (2)
Rattus (2)
Staphylococcus aureus (2)
Streptococcus pneumoniae (2)
Viruses (2)
West Nile virus (2)
cellular organisms (2)

Repository

MetaboLights (3)
pride (2)

Tissue

Blood serum (2)

Disease

Hepatocellular carcinoma (1)

Technology Type

Mass spectrometry (3)
Mass Spectrometry (2)
Affinity purification coupled with mass spectrometry proteomics (1)
Shotgun proteomics (1)

Instrument Platform

UPLC Q-TOF Premier (Waters) (2)
Agilent GC/MS, LECO GC/TOFMS (1)
5975C Series GC/MSD (Agilent) (1)

Publication Date

2015 (2)
2013 (1)
2023 (1)

CHEBI ID

CHEBI:36274 (2)
CHEBI:16525 (2)
CHEBI:27471 (2)
CHEBI:17687 (2)
CHEBI:6610|CHEBI:23527 (1)
CHEBI:40750 (1)
CHEBI:39640|CHEBI:39866 (1)
CHEBI:27471|CHEBI:36274 (1)
CHEBI:72752 (1)
CHEBI:17036 (1)
CHEBI:72742 (1)
CHEBI:72741 (1)
CHEBI:72733 (1)
CHEBI:72736 (1)
CHEBI:72735 (1)
CHEBI:72754 (1)
CHEBI:64561 (1)
CHEBI:27922 (1)
CHEBI:72721 (1)
CHEBI:72719 (1)
CHEBI:72718 (1)
CHEBI:67057 (1)
CHEBI:72715 (1)
CHEBI:28717 (1)
CHEBI:45847 (1)
CHEBI:25627 (1)
CHEBI:72693 (1)
CHEBI:15427 (1)
CHEBI:52052 (1)
CHEBI:72691 (1)

Metabolite Name

Glycodeoxycholic acid (GDCA) (2)
LPE (0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (1)
LPE (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) (1)
LPE (0:0/20:4(8Z,11Z,14Z,17Z)) (1)
LPE (20:4(8Z,11Z,14Z,17Z)/0:0) (1)
LPE (0:0/20:4(5Z,8Z,11Z,14Z) (1)
LPE (20:4(5Z,8Z,11Z,14Z)/0:0) (1)
Lythramine|cytochalasin B (1)
4-trifluoro methylaniline (1)
PS (O-18:0/0:0) (1)
LPE (20:3) (1)
LPC (15:0) (1)
Fragment of GCA (1)
Fragment of GDCA/GCDCA (1)
Taurochenodeoxycholic acid (TCDCA) (1)
Taurocholic acid (TCA) (1)
Unidentified (UM 232; RT 808) (1)
Alpha tocopherol (1)
LPC (18:0) (1)
Glutamic acid (1)
Sphingosine 1-phosphate (1)
Cholesterol (1)
PE(20:4/18:1) (1)
4E,15Z-bilirubin IXa (1)
LysoPC(20:4) (1)
CerP(d18:1/12:0) (1)
LysoPC(20:1) (1)
O-linoelaidylcarnitine (1)
Palmitylcarnitine (1)
Tetracosahexaenoic acid (1)

Lab affiliation

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. (1)
Ressom Lab, Department of Oncology, Lambardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA (1)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Human Serum LC-MS/MS - LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma

Associating changes in protein levels with the onset of cancer has proven as an effective approach to identify clinically relevant diagnostic biomarkers. In the present study, we used sera from 205 patients representing two cohorts for biomarker discovery using label-free proteomic analysis by liqui...

ORGANISM(S): Homo sapiens (Human)

2015-06-02 | PXD001171 | Pride

GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort

This study evaluates changes in metabolite levels in hepatocellular carcinoma (HCC) cases vs. patients with liver cirrhosis by analysis of human blood plasma using gas chromatography coupled with mass spectrometry (GC-MS). Untargeted metabolomic analysis of plasma samples from participants recruited...

2015-08-13 | MTBLS105 | MetaboLights

LC−MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort

Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3−5%). Early and accurate detection of metabolic changes in the...

2013-06-30 | MTBLS19 | MetaboLights

Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis

Characterizing the metabolic changes pertaining to hepatocellular carcinoma (HCC) in patients with liver cirrhosis is believed to contribute towards early detection, treatment, and understanding of the molecular mechanisms of HCC. In this study, we compare metabolite levels in sera of 78 HCC cases w...

MTBLS17 | MetaboLights

IDA (Iminodiacetic Acid) Generated Mesoporous Nanopolymer - A Template to Relate Surface Area, Hydrophilicity and Glycopeptides Enrichment

Co-polymer 1,2-epoxy-5-hexene and divinyl benzene with terminal oxirane group is synthesized for the first time. High density of hydrophilic groups (-COOH, -OH) enhances hydrophilicity through facile functionalization with Diethylene Triamine (DETA) and chloroacetic acid. COOH-functionalized mesopor...